1. Home
  2. LGVN vs CVKD Comparison

LGVN vs CVKD Comparison

Compare LGVN & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGVN
  • CVKD
  • Stock Information
  • Founded
  • LGVN 2014
  • CVKD 2022
  • Country
  • LGVN United States
  • CVKD United States
  • Employees
  • LGVN N/A
  • CVKD N/A
  • Industry
  • LGVN Medicinal Chemicals and Botanical Products
  • CVKD Medicinal Chemicals and Botanical Products
  • Sector
  • LGVN Health Care
  • CVKD Health Care
  • Exchange
  • LGVN Nasdaq
  • CVKD Nasdaq
  • Market Cap
  • LGVN 31.2M
  • CVKD 8.2M
  • IPO Year
  • LGVN 2021
  • CVKD 2023
  • Fundamental
  • Price
  • LGVN $3.29
  • CVKD $0.43
  • Analyst Decision
  • LGVN Strong Buy
  • CVKD Strong Buy
  • Analyst Count
  • LGVN 1
  • CVKD 2
  • Target Price
  • LGVN $12.00
  • CVKD $3.50
  • AVG Volume (30 Days)
  • LGVN 11.1M
  • CVKD 71.3K
  • Earning Date
  • LGVN 08-09-2024
  • CVKD 08-12-2024
  • Dividend Yield
  • LGVN N/A
  • CVKD N/A
  • EPS Growth
  • LGVN N/A
  • CVKD N/A
  • EPS
  • LGVN N/A
  • CVKD N/A
  • Revenue
  • LGVN $978,000.00
  • CVKD N/A
  • Revenue This Year
  • LGVN $137.24
  • CVKD N/A
  • Revenue Next Year
  • LGVN $50.77
  • CVKD N/A
  • P/E Ratio
  • LGVN N/A
  • CVKD N/A
  • Revenue Growth
  • LGVN N/A
  • CVKD N/A
  • 52 Week Low
  • LGVN $0.77
  • CVKD $0.36
  • 52 Week High
  • LGVN $35.60
  • CVKD $2.17
  • Technical
  • Relative Strength Index (RSI)
  • LGVN 56.11
  • CVKD 40.00
  • Support Level
  • LGVN $3.36
  • CVKD $0.43
  • Resistance Level
  • LGVN $4.88
  • CVKD $0.49
  • Average True Range (ATR)
  • LGVN 0.69
  • CVKD 0.02
  • MACD
  • LGVN 0.06
  • CVKD -0.00
  • Stochastic Oscillator
  • LGVN 37.04
  • CVKD 0.17

About LGVN Longeveron Inc.

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

Share on Social Networks: